Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment

Teenagers and young adults with nephropathic cystinosis display significant bone disease and... Background Bone impairment appears to be a novel complication of nephropathic cystinosis despite cysteamine therapy. Its exact underlying pathophysiology is nevertheless unclear. The objective of this study was to evaluate bone status among patients included in the French Crystobs study. Methods In addition to clinical data, bone status was evaluated using biomarkers (ALP, PTH, 25-D, 1-25D, FGF23), DXA (spine and total body), and high-resolution peripheral quantitative computed tomography (HR-pQCT) at the tibia and radius. Results were compared to age- and gender-matched healthy controls (1:2 basis) from the local reference cohorts. Results At a median age of 22.5 (10.2–34.6) years, 10 patients with nephropathic cystinosis were included (2 receiving conservative therapies, 2 undergoing hemodialysis, 6 with a past of renal transplantation); 7 out of 10 patients complained of a bone symptom (past of fracture, bone deformations, and/or bone pain). Biochemicals and spine DXA did not show any significant abnormalities. Using HR- pQCT, significant decreases in cortical parameters (e.g., cortical thickness 850 (520–1100) versus 1225 (480–1680) μm; p < 0.05) and total volumetric bone mineral density (290 (233–360) versus 323 (232–406) mg/cm ; p < 0.05) were observed in cystinotic patients in comparison to controls at the tibia. There were no http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatric Nephrology Springer Journals

Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/teenagers-and-young-adults-with-nephropathic-cystinosis-display-iMgZ4Og6Lt
Publisher
Springer Journals
Copyright
Copyright © 2018 by IPNA
Subject
Medicine & Public Health; Pediatrics; Nephrology; Urology
ISSN
0931-041X
eISSN
1432-198X
DOI
10.1007/s00467-018-3902-x
Publisher site
See Article on Publisher Site

Abstract

Background Bone impairment appears to be a novel complication of nephropathic cystinosis despite cysteamine therapy. Its exact underlying pathophysiology is nevertheless unclear. The objective of this study was to evaluate bone status among patients included in the French Crystobs study. Methods In addition to clinical data, bone status was evaluated using biomarkers (ALP, PTH, 25-D, 1-25D, FGF23), DXA (spine and total body), and high-resolution peripheral quantitative computed tomography (HR-pQCT) at the tibia and radius. Results were compared to age- and gender-matched healthy controls (1:2 basis) from the local reference cohorts. Results At a median age of 22.5 (10.2–34.6) years, 10 patients with nephropathic cystinosis were included (2 receiving conservative therapies, 2 undergoing hemodialysis, 6 with a past of renal transplantation); 7 out of 10 patients complained of a bone symptom (past of fracture, bone deformations, and/or bone pain). Biochemicals and spine DXA did not show any significant abnormalities. Using HR- pQCT, significant decreases in cortical parameters (e.g., cortical thickness 850 (520–1100) versus 1225 (480–1680) μm; p < 0.05) and total volumetric bone mineral density (290 (233–360) versus 323 (232–406) mg/cm ; p < 0.05) were observed in cystinotic patients in comparison to controls at the tibia. There were no

Journal

Pediatric Nephrology – Springer Journals

Published: Feb 12, 2018

References

  • Cystinosis: the evolution of a treatable disease
    Nesterova, G; Gahl, WA
  • Nephropathic cystinosis: a gap between developing and developed nations
    Bertholet-Thomas, A; Bacchetta, J; Tasic, V; Cochat, P
  • Progressive destructive bone changes in patients with cystinosis
    Klusmann, M; Hoff, W; Monsell, F; Offiah, AC
  • Cystinosis with sclerotic bone lesions
    Sirrs, S; Munk, P; Mallinson, PI; Ouellette, H; Horvath, G; Cooper, S; Roza, G; Rosenbaum, D; O'Riley, M; Nussbaumer, G; Hoang, LN; Lee, CH
  • Skeletal implications and management of cystinosis: three case reports and literature review
    Bacchetta, J; Greco, M; Bertholet-Thomas, A; Nobili, F; Zustin, J; Cochat, P; Emma, F; Boivin, G
  • Bone complications of cystinosis
    Langman, CB
  • Copper deficiency in patients with cystinosis with cysteamine toxicity
    Besouw, MTP; Schneider, J; Janssen, MC; Greco, M; Emma, F; Cornelissen, EA; Desmet, K; Skovby, F; Nobili, F; Lilien, MR; Paepe, A; Malfait, F; Symoens, S; Heuvel, LP; Levtchenko, EN
  • Cysteamine toxicity in patients with cystinosis
    Besouw, MTP; Bowker, R; Dutertre, J-P; Emma, F; Gahl, WA; Greco, M; Lilien, MR; McKiernan, J; Nobili, F; Schneider, JA; Skovby, F; Heuvel, LP; Hoff, WG; Levtchenko, EN
  • Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis
    Cherqui, S; Sevin, C; Hamard, G; Kalatzis, V; Sich, M; Pequignot, MO; Gogat, K; Abitbol, M; Broyer, M; Gubler, MC; Antignac, C
  • Pharmacokinetic studies of cysteamine bitartrate delayed-release
    Dohil, R; Rioux, P
  • Evaluation of bone and mineral disorders
    Ardeshirpour, L; Cole, DEC; Carpenter, TO
  • Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study
    Bacchetta, J; Boutroy, S; Vilayphiou, N; Ranchin, B; Fouque-Aubert, A; Basmaison, O; Cochat, P
  • Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study
    Szulc, P; Boutroy, S; Vilayphiou, N; Schoppet, M; Rauner, M; Chapurlat, R; Hamann, C; Hofbauer, LC
  • Age determines longitudinal changes in body composition better than menopausal and bone status: the OFELY study
    Sornay-Rendu, E; Karras-Guillibert, C; Munoz, F; Claustrat, B; Chapurlat, RD
  • Severe bone disease and low bone mineral density after juvenile renal failure
    Groothoff, JW; Offringa, M; Eck-Smit, BLF; Gruppen, MP; Kar, NJ; Wolff, ED; Lilien, MR; Davin, JC; Heymans, HS; Dekker, FW
  • Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study
    Denburg, MR; Kumar, J; Jemielita, T; Brooks, ER; Skversky, A; Portale, AA; Salusky, IB; Warady, BA; Furth, SL; Leonard, MB
  • Reduced fracture risk with early corticosteroid withdrawal after kidney transplant
    Nikkel, LE; Mohan, S; Zhang, A; McMahon, DJ; Boutroy, S; Dube, G; Tanriover, B; Cohen, D; Ratner, L; Hollenbeak, CS; Leonard, MB; Shane, E; Nickolas, TL
  • Osteopenia and fractures in cystinotic children post renal transplantation
    Zimakas, PJA; Sharma, AK; Rodd, CJ
  • Neurocognitive complications of cystinosis
    Trauner, D
  • Nephropathic cystinosis: an international consensus document
    Emma, F; Nesterova, G; Langman, C; Labbé, A; Cherqui, S; Goodyer, P; Janssen, MC; Greco, M; Topaloglu, R; Elenberg, E; Dohil, R; Trauner, D; Antignac, C; Cochat, P; Kaskel, F; Servais, A; Wühl, E; Niaudet, P; Hoff, W; Gahl, W; Levtchenko, E
  • Limitations of dual x-ray absorptiometry in children with chronic kidney disease
    Weber, LT; Mehls, O
  • Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidny disease
    Denburg, MR; Tsampalieros, AK; Boer, IH; Shults, J; Kalkwarf, HJ; Zemel, BS; Foerster, D; Stokes, D; Leonard, MB